Capricor Therapeutics is undergoing significant digital transformation to advance its cell and exosome-based therapies. The company is actively investing in systems and workflows to support its late-stage clinical development, manufacturing scale-up, and future commercialization efforts for its lead product, Deramiocel. This transformation focuses on managing complex biological data, streamlining regulatory submissions, and establishing robust production capabilities.
This strategic shift creates critical dependencies on advanced data management, manufacturing execution, and quality control systems. It also introduces challenges related to data integrity across clinical trials and manufacturing, as well as the need for seamless integration in commercial distribution. This page analyzes Capricor Therapeutics' key digital transformation initiatives, the operational breakdowns they create, and where sales opportunities exist.
Capricor Therapeutics Snapshot
Headquarters: San Diego, CA, United States
Number of employees: 231
Public or private: Public
Business model: B2B
Website: http://www.capricor.com
Capricor Therapeutics ICP and Buying Roles
Capricor Therapeutics sells to organizations navigating intricate R&D and manufacturing processes in the biotechnology sector.
Who drives buying decisions
- Chief Operating Officer → Oversees operational efficiency and scalability of manufacturing processes.
- Head of Clinical Operations → Manages clinical trial execution and data integrity for regulatory submissions.
- VP, Manufacturing → Directs production processes and ensures facility readiness for commercial scale.
- Director, Quality Assurance → Establishes and enforces quality standards for product development and manufacturing.
Key Digital Transformation Initiatives at Capricor Therapeutics (At a Glance)
- Expanding manufacturing operations in the San Diego facility for Deramiocel production.
- Managing clinical trial data for Biologics License Application submissions.
- Developing exosome platform manufacturing processes for StealthX™ therapeutics.
- Establishing global supply chain systems for future commercial product distribution.
- Enhancing quality management systems across manufacturing and regulatory workflows.
Where Capricor Therapeutics’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| Manufacturing Execution Systems | Expanding manufacturing operations: production batch records require manual data entry. | VP, Manufacturing | Automate data capture for batch records across production lines. |
| Expanding manufacturing operations: material tracking fails between inventory and production. | Director, Supply Chain | Enforce real-time material flow tracking within the manufacturing plant. | |
| Expanding manufacturing operations: equipment calibration data does not sync with maintenance schedules. | Head of Operations | Validate equipment readiness data before each production run. | |
| Clinical Trial Management Software | Managing clinical trial data: patient data entry causes inconsistencies in the EDC system. | Head of Clinical Operations, Director, Biometrics | Standardize data input fields within the electronic data capture system. |
| Managing clinical trial data: regulatory submission documents contain outdated patient safety information. | VP, Regulatory Affairs | Detect version discrepancies in regulatory submission packages. | |
| Managing clinical trial data: adverse event reports do not propagate to safety databases. | Medical Director | Route adverse event data to central safety monitoring systems. | |
| Laboratory Information Management Systems | Exosome platform manufacturing: sample identifiers generate mismatches in lab records. | Head of R&D, Director, Process Development | Enforce unique sample identification across all laboratory experiments. |
| Exosome platform manufacturing: raw material quality data does not link to batch analytics. | Director, Quality Control | Validate incoming material specifications against quality standards. | |
| Exosome platform manufacturing: instrument output data requires manual transfer to analytics platforms. | Lead Scientist, Lab Operations Manager | Prevent manual transcription errors from laboratory instrumentation. | |
| Supply Chain Planning Software | Global commercial supply chain: demand forecasts do not integrate with production planning. | Director, Supply Chain, Chief Commercial Officer | Standardize demand data inputs for manufacturing schedule generation. |
| Global commercial supply chain: inventory levels create stock-outs at distribution hubs. | Supply Chain Manager | Prevent stock depletion by correlating sales orders with warehouse stock. | |
| Global commercial supply chain: logistics data fails to update order fulfillment status. | Head of Logistics | Route real-time shipping updates to customer service systems. | |
| Quality Management Systems | Quality management systems: deviation reports remain open without corrective actions. | Director, Quality Assurance, Head of QA/QC | Detect open deviations that exceed predefined closure timelines. |
| Quality management systems: audit findings do not trigger CAPA initiation. | VP, Quality | Enforce CAPA creation directly from audit observation records. | |
| Quality management systems: training records do not validate employee qualifications for specific tasks. | Head of HR, Director, Training | Verify employee certifications before assigning critical manufacturing tasks. |
Identify when companies like Capricor Therapeutics are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Capricor Therapeutics’s digital transformation unique
Capricor Therapeutics' digital transformation prioritizes the integration of complex biological research with scalable manufacturing and rigorous regulatory compliance. Unlike typical companies, they depend heavily on precise data management for cell and exosome-based therapies, where every data point can impact patient safety and product efficacy. Their approach involves building out systems that support both cutting-edge scientific development and the strict requirements for FDA approval and commercial distribution. This dual focus makes their transformation more complex, balancing innovation with stringent quality and regulatory controls.
Capricor Therapeutics’s Digital Transformation: Operational Breakdown
DT Initiative 1: Expanding manufacturing operations in the San Diego facility for Deramiocel production.
What the company is doing
Capricor Therapeutics is scaling up its production capacity for Deramiocel at its new San Diego manufacturing facility. This involves implementing new production lines and optimizing existing workflows to meet anticipated commercial demand.
Who owns this
- VP, Manufacturing
- Head of Operations
- Director, Facilities Management
Where It Fails
- Production equipment data requires manual input into the Manufacturing Execution System.
- Material transfer logs create discrepancies between warehouse and production inventories.
- Maintenance schedules do not align with real-time equipment performance data.
- Environmental monitoring records for cleanrooms fail to update central compliance dashboards.
Talk track
Noticed Capricor Therapeutics is significantly expanding its Deramiocel manufacturing operations in San Diego. Been looking at how some biotech companies are automating their production equipment data capture instead of relying on manual entry, can share what’s working if useful.
DT Initiative 2: Managing clinical trial data for Biologics License Application submissions.
What the company is doing
Capricor Therapeutics is actively collecting and analyzing data from its Phase 3 HOPE-3 clinical trials for Deramiocel. This data supports its ongoing Biologics License Application (BLA) submissions to the FDA. They are preparing clinical study reports and other supporting documents for regulatory review.
Who owns this
- Head of Clinical Operations
- VP, Regulatory Affairs
- Director, Biometrics
- Chief Medical Officer
Where It Fails
- Patient data from clinical sites creates discrepancies in the Electronic Data Capture system.
- Regulatory submission packages contain unversioned clinical study reports.
- Adverse event data from trial sites does not consistently propagate to safety monitoring systems.
- Data quality checks on patient outcomes require extensive manual verification before analysis.
Talk track
Saw Capricor Therapeutics is managing complex clinical trial data for BLA submissions. Been looking at how some pharmaceutical teams are standardizing data input fields in their EDC systems instead of correcting inconsistencies later, happy to share what we’re seeing.
DT Initiative 3: Developing exosome platform manufacturing processes for StealthX™ therapeutics.
What the company is doing
Capricor Therapeutics is advancing its proprietary StealthX™ exosome platform for targeted drug delivery and vaccines. This involves developing scalable methods for loading therapeutic molecules into exosomes and streamlining their production. They are moving this platform from preclinical development into early-stage clinical trials.
Who owns this
- Head of R&D
- VP, Process Development
- Director, Analytical Development
- Chief Scientific Officer
Where It Fails
- Exosome production runs generate inconsistent batch yields between different process development stages.
- Raw material quality data for exosome manufacturing does not link to final product specifications.
- Loading efficiency data for therapeutic payloads requires manual correlation with exosome purity results.
- Laboratory instrument output for exosome characterization fails to integrate with central data repositories.
Talk track
Looks like Capricor Therapeutics is developing advanced manufacturing processes for its StealthX™ exosome platform. Been seeing teams enforce unique sample identification across all laboratory experiments instead of managing data silos, can share what’s working if useful.
DT Initiative 4: Establishing global supply chain systems for future commercial product distribution.
What the company is doing
Capricor Therapeutics is preparing for the commercial launch of Deramiocel, including setting up systems for global distribution and logistics. This involves managing partnerships and ensuring product availability across various regions. They are focused on building commercial readiness.
Who owns this
- Chief Commercial Officer
- VP, Supply Chain
- Director, Logistics
- Head of Distribution
Where It Fails
- Demand forecasts from commercial partners do not integrate with internal production schedules.
- Shipping tracking data generates delays in updating inventory levels at regional distribution centers.
- Serialization data for individual product units creates mismatches with global regulatory requirements.
- Supplier performance metrics fail to provide real-time insights into material availability.
Talk track
Noticed Capricor Therapeutics is establishing global supply chain systems for commercial product distribution. Been looking at how some biotech companies are standardizing demand data inputs for manufacturing schedule generation instead of adjusting for manual discrepancies, happy to share what we’re seeing.
DT Initiative 5: Enhancing quality management systems across manufacturing and regulatory workflows.
What the company is doing
Capricor Therapeutics is strengthening its quality management systems (QMS) to ensure compliance with GMP (Good Manufacturing Practice) standards and regulatory requirements. This includes processes for quality assurance, quality control, and document management throughout the product lifecycle. They are hiring for key quality roles to support these efforts.
Who owns this
- VP, Quality
- Director, Quality Assurance
- Head of Regulatory Compliance
- Chief Quality Officer
Where It Fails
- Deviation reports across manufacturing sites do not consolidate into a single QMS database.
- Corrective and Preventative Action (CAPA) plans fail to link directly to originating audit findings.
- Employee training records do not validate required certifications for specific production tasks.
- Document control processes generate outdated Standard Operating Procedure versions on the plant floor.
Talk track
Seems like Capricor Therapeutics is enhancing its quality management systems across manufacturing and regulatory workflows. Been seeing teams detect open deviations that exceed predefined closure timelines instead of manually tracking follow-ups, can share what’s working if useful.
Who Should Target Capricor Therapeutics Right Now
This account is relevant for:
- Manufacturing Execution System (MES) providers
- Clinical Data Management System (CDMS) vendors
- Laboratory Information Management System (LIMS) platforms
- Biologics Supply Chain Management providers
- Enterprise Quality Management System (EQMS) vendors
Not a fit for:
- Basic office productivity software providers
- Standalone marketing automation platforms
- General IT consulting firms without biotech specialization
- Consumer-facing e-commerce solutions
When Capricor Therapeutics Is Worth Prioritizing
Prioritize if:
- You sell systems that automate data capture for production batch records in biotech manufacturing.
- You sell solutions that standardize data input fields within electronic data capture systems for clinical trials.
- You sell platforms that enforce unique sample identification across laboratory information management systems.
- You sell tools that integrate demand forecasts with production schedules for biologics supply chains.
- You sell software that detects open quality deviations and links them to corrective actions in a quality management system.
Deprioritize if:
- Your solution does not address specific data integrity or workflow breakdowns in pharmaceutical R&D or manufacturing.
- Your product is limited to basic functionality without regulatory compliance features for biotech.
- Your offering is not designed for complex biological manufacturing or clinical trial environments.
Who Can Sell to Capricor Therapeutics Right Now
Manufacturing Execution Systems (MES)
Rockwell Automation (FactoryTalk ProductionCentre) - This company offers a comprehensive MES that integrates production operations, quality, and inventory management for manufacturing.
Why they are relevant: Capricor Therapeutics' expanding manufacturing operations require automated data capture for batch records. Rockwell Automation can enforce real-time data collection from production equipment and prevent manual data entry errors in the Manufacturing Execution System.
Siemens (SIMATIC IT Unified Architecture) - This company provides an MES platform designed to manage and synchronize manufacturing processes across plants.
Why they are relevant: Material tracking often fails between inventory and production at Capricor Therapeutics' new facility. Siemens SIMATIC IT can implement real-time material flow tracking, linking raw material usage to specific production batches and reducing inventory discrepancies.
Honeywell (Experion Process Knowledge System) - This company offers integrated control and safety systems, including MES capabilities for process industries.
Why they are relevant: Equipment calibration data at Capricor Therapeutics does not sync with maintenance schedules. Honeywell Experion can automate the collection and integration of equipment performance and calibration data, ensuring that maintenance is proactively scheduled and executed.
Clinical Data Management Systems (CDMS)
Medidata Solutions (Rave Clinical Cloud) - This company provides an integrated platform for clinical research, including electronic data capture (EDC) and clinical trial management (CTMS).
Why they are relevant: Patient data entry causes inconsistencies in Capricor Therapeutics' EDC system. Medidata Rave can standardize data input fields and implement real-time validation checks within the electronic data capture system, improving data quality from clinical sites.
Veeva Systems (Veeva Clinical Vault) - This company offers cloud-based software for managing clinical operations, data, and regulatory documents.
Why they are relevant: Regulatory submission documents at Capricor Therapeutics sometimes contain outdated patient safety information. Veeva Clinical Vault can manage document versions and ensure that the most current clinical study reports and safety data are included in regulatory submission packages, preventing version discrepancies.
Oracle (Oracle Health Sciences Clinical One) - This company delivers a unified clinical platform for managing trials from study startup to submission.
Why they are relevant: Adverse event reports do not consistently propagate to safety databases at Capricor Therapeutics. Oracle Clinical One can route adverse event data automatically from clinical sites to central safety monitoring systems, ensuring timely reporting and analysis.
Laboratory Information Management Systems (LIMS)
Thermo Fisher Scientific (SampleManager LIMS) - This company provides a LIMS that manages laboratory samples, tests, results, and instrumentation.
Why they are relevant: Sample identifiers at Capricor Therapeutics sometimes generate mismatches in lab records. SampleManager LIMS can enforce unique sample identification and tracking across all laboratory experiments, preventing data integrity issues in exosome platform manufacturing.
LabWare (LIMS) - This company offers an enterprise LIMS solution designed to automate laboratory operations and data management.
Why they are relevant: Raw material quality data for exosome manufacturing at Capricor Therapeutics does not consistently link to batch analytics. LabWare LIMS can validate incoming material specifications against predefined quality standards and integrate this data with batch analytics for exosome production.
STARLIMS (LIMS Solution) - This company provides a web-based LIMS that supports laboratory workflows, quality control, and compliance.
Why they are relevant: Laboratory instrument output for exosome characterization requires manual transfer to analytics platforms at Capricor Therapeutics. STARLIMS can integrate directly with laboratory instrumentation, preventing manual transcription errors and ensuring automated data capture for exosome characterization.
Enterprise Quality Management Systems (EQMS)
MasterControl (Quality Excellence Platform) - This company offers an EQMS platform to manage quality documents, training, deviations, and CAPAs in regulated industries.
Why they are relevant: Deviation reports at Capricor Therapeutics remain open without proper corrective actions. MasterControl can detect open deviations that exceed predefined closure timelines and enforce automated routing for follow-up and resolution within the QMS database.
Sparta Systems (TrackWise Digital) - This company provides a cloud-based EQMS solution for managing quality processes, including audit management and CAPA.
Why they are relevant: Audit findings at Capricor Therapeutics do not consistently trigger CAPA initiation. TrackWise Digital can enforce CAPA creation directly from audit observation records, ensuring that all findings lead to appropriate corrective and preventive actions.
ETQ (Reliance QMS) - This company offers a quality management system that automates quality processes and ensures compliance.
Why they are relevant: Employee training records at Capricor Therapeutics do not validate required qualifications for specific production tasks. Reliance QMS can verify employee certifications and training compliance before assigning critical manufacturing tasks, improving adherence to quality standards.
Final Take
Capricor Therapeutics is scaling its manufacturing capacity and advancing its clinical trial data management to support its lead therapeutic, Deramiocel. Breakdowns are visible in manual data handling across production records, inconsistencies in clinical data capture, and fragmented quality management processes. This account is a strong fit for solutions that bring automation, data integrity, and compliance enforcement to complex biotech manufacturing, R&D, and quality workflows.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.